Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

MLA

Berdel, Andrew F., et al. “Using Stroma-Anchoring Cytokines to Augment ADCC: A Phase 1 Trial of F16IL2 and BI 836858 for Posttransplant AML Relapse.” Blood Advances, vol. 6, no. 12, June 2022, pp. 3684–96. EBSCOhost, https://doi.org/10.1182/bloodadvances.2021006909.

APA

Berdel, A. F., Ruhnke, L., Angenendt, L., Wermke, M., Röllig, C., Mikesch, J.-H., Scheller, A., Hemmerle, T., Matasci, M., Wethmar, K., Kessler, T., Gerwing, M., Hescheler, D., Schäfers, M., Hartmann, W., Altvater, B., Rossig, C., Bornhäuser, M., Lenz, G., … Schliemann, C. (2022). Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. Blood Advances, 6(12), 3684–3696. https://doi.org/10.1182/bloodadvances.2021006909

Chicago

Berdel, Andrew F, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Röllig, Jan-Henrik Mikesch, Annika Scheller, et al. 2022. “Using Stroma-Anchoring Cytokines to Augment ADCC: A Phase 1 Trial of F16IL2 and BI 836858 for Posttransplant AML Relapse.” Blood Advances 6 (12): 3684–96. doi:10.1182/bloodadvances.2021006909.